Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $16.0052W HIGH $31.34
Volume
491.13 K
Value Traded
19.58 M
Short % Float
7.17%
-1.6%Week
-2.44%1 Month
+3.41%3 Month
-1.45%6 Month
-14.43%5 Year
+89.7%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.83 B
EPS (TTM)
-2.10
P/E Ratio
-
Ent. Value
1.51 B
Total Shares
70.96 M
Float Shares
68.92 M
Insiders
3.63%
Institutions
99.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ZYME Catalyst Timeline
Dated clinical, regulatory and corporate events for Zymeworks Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zymeworks Inc.
297Total events
26Upcoming
75Tier-1 (high impact)
2022 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Timing GuidancePresentation
Webcast replay available within 24 hours following conclusion of call
●Timing GuidancePresentation
Cumulatively utilized $211.6 million to reacquire 10,571,316 shares at average price of $20.02
▲FDA ApprovalZiiheraApprovedFDA Decision
FDA approves Ziihera (zanidatamab-hrii) for first-line HER2-positive advanced gastroesophageal adenocarcinoma
first-line HER2-positive advanced gastroesophageal adenocarcinomasource ↗
▲Milestone PaymentZanidatamabApprovedCorporate
Zymeworks earns $250 million milestone payment from Jazz Pharmaceuticals upon FDA approval
▲Partnership / LicenseCorporate
Partnership with Gandeeva to use cryo-EM for antibody drug discovery
▲Oral PresentationZW191Presentation
Presented new Phase 1 data for ZW191 at ESMO Gynaecological Cancers Congress 2026
platinum-resistant ovarian cancer, endometrial cancersource ↗
▲Enrollment CompleteZW191Trial
Completed enrollment in Part 2a dose optimization cohort (~60 PROC patients randomized to 6.4 or 9.6 mg/kg Q3W)
platinum-resistant ovarian cancersource ↗
◆Oral PresentationZanidatamabApprovedPresentation
Jazz to present PD-L1 subgroup data from HERIZON-GEA-01 at ASCO
first-line HER2-positive GEAsource ↗
◆Interim AnalysisZanidatamabApprovedTrial
Second interim overall survival analysis for HERIZON-GEA-01 expected mid-2026
first-line HER2-positive GEAsource ↗
▲Runway Guidance UpdateCorporate
Expect cash resources to fund operations beyond 2028, including anticipated milestone payments
●Timing GuidancePresentation
Reiterated adjusted gross operating expense guidance of ~$300M over three years ending Dec 2028
▲Corporate ApprovalCorporate
Board authorized 2026 share repurchase program of up to $125.0 million
◆Oral PresentationZW191Presentation
Oral presentation of Part 1 dose escalation results from Phase 1 trial of ZW191
advanced solid tumorssource ↗
▲Enrollment CompleteZW191Trial
Part 2a dose-optimization enrollment completed for ZW191 in ovarian cancer
ovarian cancersource ↗
◆Poster PresentationZW427Presentation
Poster presentation on ZW427, a Ly6E-targeting ADC with pan-RAS inhibitor payload
RAS mutated cancerssource ↗
◆Poster PresentationZW439Presentation
Poster presentation on ZW439, a CLDN18.2-targeting pan-RAS inhibitor ADC
RAS mutated pancreatic cancersource ↗
◆Poster PresentationZW191Presentation
Poster presentation on ZW191 combination with standard of care drugs
advanced solid tumorssource ↗
◆Poster PresentationZW437Presentation
Poster presentation on pan-RASi ADC platform (ZW437)
RAS-mutant cancerssource ↗
◆Poster PresentationZW418PreclinicalPresentation
Poster presentation on ZW418, a biparatopic PTK7-targeting ADC with pan-RAS inhibitor payload
non-small cell lung cancersource ↗
◆Poster PresentationPresentation
Poster presentation on mRNA translation inhibitors as ADC payloads
cancersource ↗
●Management ChangeCorporate
Appointed Scott Platshon as EVP Chief Business Officer effective April 9, 2026
▲FDA Filing AcceptedZanidatamabApprovedRegulatory Filing
U.S. FDA accepted sBLA for zanidatamab with Priority Review
first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinomasource ↗
▲Breakthrough Therapy DesignationZanidatamabApprovedDesignation
FDA granted Breakthrough Therapy Designation to zanidatamab in combination with chemotherapy and TEVIMBRA
first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinomasource ↗
●Oral PresentationZanidatamabApprovedPresentation
Jazz presented three posters and an oral presentation at AACR on zanidatamab
HER2-expressing solid tumorssource ↗
▲Poster PresentationZW191Presentation
Presented new Phase 1 data for ZW191 at AACR
ovarian and endometrial cancerssource ↗
●Poster PresentationZW418PreclinicalPresentation
Presented preclinical data on RAS inhibitor ADC platform and three candidates at AACR
RAS mutated cancerssource ↗
▲Priority ReviewZanidatamabApprovedRegulatory Filing
FDA granted Priority Review to sBLA for zanidatamab
first-line HER2-positive unresectable locally advanced or metastatic GEAsource ↗
▲Priority ReviewtislelizumabFiledRegulatory Filing
FDA granted Priority Review to sBLA for TEVIMBRA in combination with Ziihera and chemo
first-line HER2+ gastric/GEJ/esophageal adenocarcinomasource ↗
▲FDA Filing AcceptedtislelizumabFiledRegulatory Filing
China NMPA accepted sBLA for tislelizumab based on HERIZON-GEA-01 data
first-line HER2+ GEAsource ↗
▲Fast Track DesignationZW191Designation
FDA Fast Track designation granted for ZW191 in PROC
advanced or metastatic platinum-resistant ovarian cancer (PROC)source ↗
▲Trial InitiationZW191Trial
Phase 1 clinical trial of ZW191 ongoing, enrolling patients
advanced solid tumorssource ↗
▲Debt Royalty FinancingCorporate
Zymeworks enters into $250 million royalty-backed note financing with Royalty Pharma
▲Debt Royalty FinancingZanidatamabApprovedCorporate
$250M non-recourse royalty-backed note financing from Royalty Pharma
Past FDA Catalysts and PDUFA Decisions
How ZYME actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | zanidatamab (Ziihera) | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C42 / 100
Pipeline Score
$148M
Pipeline Value
$88M
Commercial Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 35%
Micro Cap(rank 232 of 660)
Percentile Rank
Zymeworks Inc. carries a moderate pipeline score (42/100), with $369M risk-adjusted pipeline value, led by ZW49 in HER2-expressing Cancers (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Jun 2026) Revenue $37.1M x 2.4 = $88M
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ZW49 Small moleculeCompletedNCT03821233 | HER2-expressing Cancers | Phase 1 | COMPLETED | 112 | Oct 8, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every ZYME program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ZW191 Fast Track | platinum-resistant ovarian cancer and endometrial cancer | Phase 1 | 2026-06-14 | c ORR FRα positive: 78.6%; c ORR FRα negative: 47.4%; overall c ORR: 58.8%; c ORR dose range: 65.2%; c ORR endometrial FRα negative: 40.0%; disease control rate FRα positive: 100.0%; disease control rate FRα negative: 89.5%; median progression free survival: 7.6 monthsRead More | Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Schayowitz AdamOfficer (EVP, Head of R&D) | Option | 37,037 37,037 held | $0.00 | 10/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ZYME
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 29.2 % (19.7 %) | 600.45 M | 22.97 M |
ZYME Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ZYME ranks across every disease it competes in
Competitive Position is a premium feature
See how ZYME ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialZYME News
ZYMEZymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Zymeworks has completed its acquisition of Theravance Biopharma, which adds YUPELRI to its portfolio, expected to generate significant revenue and cash flow. The company anticipates total revenue for 2026 to be between $278 million and $292 million, with adjusted EBITDA between $114 million and $128 million. Zymeworks plans to retain the existing commercial team for YUPELRI and aims to leverage new tax attributes from the acquisition.
Read more →ZYMEZymeworks Completes Acquisition of Theravance Biopharma
Zymeworks Inc. has successfully completed the acquisition of Theravance Biopharma, enhancing its strategy to build a diversified biotechnology company. This acquisition is expected to generate revenue through innovative research and development efforts. A conference call is scheduled for September 28 to discuss the transaction details.
Read more →ZYME▼ -7.5%on this news
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
The U.S. FDA has approved Ziihera (zanidatamab-hrii) for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma, both with and without tislelizumab. This marks the second FDA approval for zanidatamab in under two years, highlighting Zymeworks' successful drug development strategy. The approval triggers a $250 million milestone payment from Jazz Pharmaceuticals, with potential for additional earnings.
Read more →ZYMEZymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. has announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and Citi's Biopharma Back to School Summit. Management will engage in one-on-one meetings and fireside chats at these events, showcasing the company's commitment to investor relations. Zymeworks continues to develop a diverse pipeline of biotherapeutics aimed at improving care for challenging diseases.
Read more →ZYMEZymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Zymeworks announced a corporate update highlighting a U.S. PDUFA target action date for zanidatamab, which could lead to a $250 million milestone upon approval. Additionally, the company anticipates closing its acquisition of Theravance Biopharma, Inc. in the second half of 2026, which may strengthen its market position.
Read more →ZYMEZymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Zymeworks Inc. will report its second quarter 2026 financial results on August 6, 2026. The company has opted not to hold an earnings conference call due to the proposed acquisition of Theravance Biopharma. Following the acquisition, Zymeworks plans to provide updates on the combined business and its strategic priorities.
Read more →ZYMEZymeworks to Acquire Theravance Biopharma, Inc.
Zymeworks has announced its acquisition of Theravance Biopharma for $17 per share, totaling approximately $929 million. This acquisition includes YUPELRI®, the only approved nebulized LAMA for COPD, which is expected to enhance Zymeworks' portfolio and generate significant cash flow. The deal is supported by a non-recourse financing structure, minimizing capital risk and is anticipated to close in the second half of 2026.
Read more →ZYMEGandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
Gandeeva Therapeutics and Zymeworks have formed a partnership to utilize cryo-electron microscopy (cryo-EM) for antibody drug discovery. This collaboration aims to visualize antibody-antigen interfaces at high resolution, particularly focusing on small and flexible antigens. The ability to obtain near-atomic resolution structures is expected to significantly enhance the selection and optimization of antibody leads.
Read more →ZYMEZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Zymeworks presented promising Phase 1 data for ZW191, an antibody-drug conjugate targeting folate receptor alpha, at the ESMO Gynaecological Cancers Congress 2026. The data revealed a confirmed objective response rate of 78.6% in FRα-positive ovarian cancer patients and 47.4% in FRα-negative patients. The therapy exhibited a favorable safety profile, with manageable adverse events, supporting its continued clinical development.
Read more →ZYMEPhase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Read more →ZYMEZymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
Zymeworks Inc. has announced a share repurchase program allowing for the repurchase of up to $125 million of its common stock. This decision is part of a strategic initiative to enhance capital allocation and provide returns to shareholders, while also preserving financial flexibility to invest in research and development projects. The company has terminated its previous repurchase program from 2025, having bought back over 4 million shares. The new program demonstrates Zymeworks' focus on long-term value creation.
Read more →ZYMEZymeworks Announces Participation in Upcoming Investor Conferences - May 13, 2026
Zymeworks Inc. announced its participation in upcoming investor conferences, highlighting its commitment to engaging with the investment community. The company is focused on managing a portfolio of licensed healthcare assets and developing innovative biotherapeutics targeting difficult-to-treat diseases. Zymeworks continues to advance its pipeline, leveraging proprietary technology and strategic partnerships.
Read more →ZYME▼ -10.2%on this newsshared move
Zymeworks to Present at Respiratory Innovation Summit
Zymeworks will present its bispecific antibody ZW1528 at the Respiratory Innovation Summit on May 15-16, 2026. This novel treatment targets respiratory inflammation associated with COPD by inhibiting multiple cytokines. The company aims to connect with attendees to discuss its AIID programs and the potential benefits of ZW1528, which shows promise in preclinical studies.
Read more →ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Zymeworks Inc. reported its financial results for Q1 2026, highlighting significant regulatory achievements for zanidatamab, which has a PDUFA date set for August 25, 2026. The company also shared promising clinical data for ZW191, showing a 56% objective response rate in ovarian cancer patients. Zymeworks is financially robust, with $403.8 million in cash and equivalents. Additionally, changes to the leadership team were announced to improve strategic execution.
Read more →ZYMEJazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Read more →ZYMEZymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
Zymeworks presented promising Phase 1 data for ZW191, an ADC targeting folate receptor alpha, at the AACR Annual Meeting 2026. The therapy showed a 61% confirmed objective response rate in platinum-resistant ovarian cancer and demonstrated manageable safety. The study supports further development of ZW191 for patients with limited treatment options in ovarian and endometrial cancers.
Read more →ZYMEZymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Read more →ZYMEZymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
Zymeworks Inc. will report its first quarter 2026 financial results on May 7, 2026, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss the results and provide a corporate update. The event will be accessible via Zymeworks' website.
Read more →ZYMEZymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
Zymeworks Inc. has appointed Dr. Adam Schayowitz as Head of R&D and Scott Platshon as Chief Business Officer, transitioning from interim roles. These appointments aim to enhance the company's clinical development and strategic asset management. Recent milestones, including positive Phase 3 data for zanidatamab, highlight Zymeworks' growth strategy and commitment to innovation in biotherapeutics.
Read more →About Zymeworks Inc.
Headquarters108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
BIOPHARMAWATCH ELITE PLUS
Trade the next ZYME catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime